annual meeting program - American Society of Clinical Oncology

SATURDAY
Saturday, June 5, 2010
Brd. 23G A double-blind, randomized, prospective, phase II trial of capecitabine (Cap)
plus enzastaurin (Enz) versus cap plus placebo in patients (pts) with
advanced breast cancer (BrCa) and prior anthracycline and taxane treatment.
(Abstract #1054)
M. Clemons, K. A. Gelmon, J. Lynch, M. L. Kotliar, A. Joy, J. P. Jordaan, L. L. Han,
J. M. Blair, N. A. Iscoe
Brd. 23H Correlations between efficacy and early changes in biomarkers in a
metastatic breast cancer (mBC) clinical trial with sunitinib malate. (Abstract
#1055)
K. Keyvanjah, W. Carley, Oncology Business Unit, Pfizer Global Research and
Development
Brd. 24A Candidate predictive biomarkers of cetuximab benefit in triple-negative
breast cancer. (Abstract #1056)
S. Khambata-Ford, J. O’Shaughnessy, D. Brickman, J. D. Jensen, L. Asmar,
C. E. Horak
Brd. 24B Risk of renal failure associated with IV bisphosphonate use in patients with
metastatic breast cancer. (Abstract #1057)
W. J. Langeberg, K. Chung, M. J. Lage
Brd. 24C Age-specific trends of survival in metastatic breast cancer: Data from a
population-based cancer registry in Stockholm, Sweden. (Abstract #1058)
T. Foukakis, T. Fornander, T. Lekberg, H. Hellborg, J. Adolfsson, J. Bergh,
on behalf of the Stockholm Breast Cancer Study Group
Brd. 24D Correlation of efficacy between EGFR gene copy number and
lapatinib/capecitabine therapy in HER2-positive metastatic breast cancer.
(Abstract #1059)
A. Fabi, A. Di Benedetto, R. Merola, G. Metro, M. Mottolese, P. Papaldo,
G. Ferretti, P. Vici, I. Sperduti, F. Cognetti
Brd. 24E Safety and efficacy of low-dose metronomic chemotherapy with capecitabine
in heavily pretreated patients with metastatic breast. (Abstract #1060)
P. Fedele, L. Orlando, P. Schiavone, P. Rizzo, N. Calvani, M. D’Amico, A. Marino,
F. Sponziello, A. Nacci e S. Cinieri
Brd. 24F Long-term effect of fulvestrant on signaling elements in breast cancer.
(Abstract #1061)
A. Agrawal, J. F. Robertson, E. Gutteridge, I. O. Ellis, K. Cheung, R. I. Nicholson,
S. Kyme, J. M. Gee
Brd. 24G Phase II study of bavituximab plus paclitaxel and carboplatin in locally
advanced or metastatic breast cancer: Interim results. (Abstract #1062)
M. Jain, N. Raizada, R. Kuttan, J. Shan, R. Digumarti
Brd. 24H Risk factors for central nervous system (CNS) metastases in patients with
stage I-III breast cancer. (Abstract #1063)
S. P. Neciosup, H. L. Gomez, W. R. Cruz, F. F. Doimi, J. A. Pinto, J. M. Cotrina,
J. F. Suazo, V. E. Carlos, L. Mauricio, C. Vallejos Sologuren
Brd. 25A Impact of CNS metastases on treatment and survival in patients receiving
trastuzumab for metastatic breast cancer (MBC). (Abstract #1064)
R. Griffiths, K. Lindquist, D. Lalla, J. F. Doan, M. G. Brammer, M. Danese
Brd. 25B BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase
inhibitor, for the treatment of patients with HER2-negative metastatic breast
cancer after failure of no more than two prior chemotherapies. (Abstract
#1065)
M. H. Schuler, M. M. Uttenreuther-Fischer, M. J. Piccart-Gebhart, N. Harbeck,
on behalf of the study group and trial team
Brd. 25F Pertuzumab and trastuzumab: Exploratory biomarker correlations with
clinical benefit in patients with metastatic HER2-positive breast cancer.
(Abstract #1066)
J. Cortes, J. Baselga, P. Fumoleau, K. A. Gelmon, G. Ross, V. McNally,
G. V. Bianchi, M. Venturi, H. Paul, L. Gianni
160